Daniel M. Bloomfield M.D., MPhil, FACC, FAHA is a physician-scientist and industry executive with a diverse career that spans years of effective collaboration across a worldwide organization, partnership with the FDA, leading development programs to completion and shaping the future of cardiac safety in drug development within a changing regulatory environment. Prior to Cardurion Pharmaceuticals, Dan was senior vice president, global clinical development at Merck Research Laboratories, and was the therapeutic area head for Cardiometabolic and Women’s Health Programs. In addition to leading this therapeutic area, Dr. Bloomfield was responsible for the central coordination and strategic oversight of Merck’s R&D organization in China across all therapeutic areas. Dr. Bloomfield was chosen to chair the Early Development Research Committee which governs all programs in early development, was appointed head of global project management, and subsequently spent one year on assignment as chief of staff to the CEO Kenneth C. Frazier. Dr. Bloomfield received his B.A. from Haverford College in chemistry and took a Master’s degree at the University of Oxford as a Rhodes Scholar. Upon his return to the US, he attended Harvard Medical School and subsequently did his Internal Medicine and Cardiology training at Columbia before joining the faculty upon graduation.